Rick Bienkowski
Stock Analyst at Ladenburg Thalmann & Co.
(0.12)
# 4,563
Out of 4,630 analysts
46
Total ratings
18.8%
Success rate
-23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $4.09 | - | 1 | Jul 30, 2026 | |
| PMVP PMV Pharmaceuticals | Initiated Coverage: Buy | $3 | $1.19 | +152.10% | 1 | Jul 8, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | n/a | $27.48 | - | 13 | Aug 19, 2025 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $65 | $11.94 | n/a | 6 | May 29, 2025 | |
| LEGN Legend Biotech | Maintained: Buy | $83 → $55 | $20.75 | n/a | 4 | May 13, 2025 | |
| CRBU Caribou Biosciences | Initiated Coverage: Hold | n/a | $1.65 | n/a | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Downgraded: Hold | n/a | $2.88 | n/a | 13 | Oct 17, 2023 | |
| LON: OXB Oxford Biomedica plc | Initiated Coverage: Buy | 840p | 505p | n/a | 1 | May 3, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $112 → $107 | $53.52 | n/a | 6 | Aug 8, 2022 |
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.09
Upside: -
PMV Pharmaceuticals
Jul 8, 2026
Initiated Coverage: Buy
Price Target: $3
Current: $1.19
Upside: +152.10%
Beam Therapeutics
Aug 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $27.48
Upside: -
Intellia Therapeutics
May 29, 2025
Reiterated: Buy
Price Target: $65
Current: $11.94
Upside: n/a
Legend Biotech
May 13, 2025
Maintained: Buy
Price Target: $83 → $55
Current: $20.75
Upside: n/a
Caribou Biosciences
Nov 8, 2023
Initiated Coverage: Hold
Price Target: n/a
Current: $1.65
Upside: n/a
Editas Medicine
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $2.88
Upside: n/a
Oxford Biomedica plc
May 3, 2023
Initiated Coverage: Buy
Price Target: 840p
Current: 505p
Upside: n/a
CRISPR Therapeutics AG
Aug 8, 2022
Reiterated: Buy
Price Target: $112 → $107
Current: $53.52
Upside: n/a